AbbVie's Rinvoq approved in EU for juvenile idiopathic arthritis
AbbVie Inc. announced that the European Commission has approved Rinvoq (Upadacitinib) for the treatment of children with active polyarticular juvenile idiopathic arthritis, aged two years and older.
: Abbvie Announces European Commission Approval Of Rinvoq® (Upadacitinib) For The Treatment Of Children With Active Polyarticular Juvenile Idiopathic Arthritis Abbvie - Rinvoq Approved In Eu For Pjia In Patients Aged Two Years And Older Source text:... com;)